DP -GP方案随机对照治疗晚期非小细胞肺癌.DOCVIP

临床医学论文-DP /GP方案随机对照治疗晚期非小细胞肺癌 【关键词】? 多西他赛；吉西他滨；顺铂；癌,非小细胞肺 ??? ［摘要］? 目的? 评估吉西他滨联合顺铂与多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法? DP 方案组（A组）：多西他赛（docetaxel）75 mg/m2，静滴，第1天，顺铂（CDDP）25 mg/m2，静滴，第2~4天，每3周重复；GP方案组（B组）：吉西他滨（gemcitabine）1250 mg/m2，静滴，第1、8天，顺铂（CDDP）25 mg/m2，静滴，第2~4天，每3周重复。治疗2周期评价疗效，每周评价毒性反应。结果?? 两组有效率分别为47.1%和41.2%，中位疾病进展时间分别为5.8个月和6.1个月，1年生存率分别为 44.1%和41.2%，差异均无显著性（P＞0.05），中位生存期分别为11.4个月和8.1个月，差异有显著性（P＜0.05），B组血小板减少明显高于A 组，其他不良反应两组接近。结论? A、B组有效率、中位疾病进展时间、1年生存率相似，但中位生存期A组优于B 组。 ??? ［关键词］? 多西他赛；吉西他滨；顺铂；癌，非小细胞肺 ??? Docetaxel/cisplatin and gemcitabine/cisplatin for the treatment of advanced? non-small-cell lung cancer:a randomized,control trial ?????? ［Abstract］? Objective? To assess the clinical response and toxicity of docetaxel/cisplatin and gemcitabine/cisplatin for the treatment of advanced? non-small-cell lung cancer.Methods? Group A:docetaxel 75mg/m2 iv，d1,cisplatin 25 mg/m2 iv，d2~4，q3w;Group B:gemcitabine 1250mg/m2 iv,d1 and d8,cisplatin 25mg/m2 iv，d2~4，q3w.The clinical responses were assessed after two cycles,toxicity was assessed every cycle.Results? The clinical response rate were 47.0% and 41.2% in group A and B, the median progression were 5.8 and 6.1 months,one-year survival were 44.1% and 41.2% respectively.No statistical difference existed between the two groups.The median survival were 11.4 and 8.6 months,with statistical difference（P＜0.05）;the rate of thrombocytopenia in group B were higher than group A,the rate of other toxicityin in group B was similar to group A.Conclusion? The clinical response,the median progression,one-year survival are approximate in group A and B,But the median survival in group A was higher than group B. ??? ［Key words］? gemcitabine;docetaxel;cisplatin;carcinoma,no-small-cell lung ??? 目前肺癌是世界上最常见的恶性肿瘤，全世界每年大约有140万例新诊断的肺癌，其中超过80%是非小细胞肺癌（NSCLC）［1］。近10年中，肺癌的研究虽已取得不少成绩，但确诊时通常只有20%~30%的患者能够进行根治性手术，其余的患者则属于局部晚期或远处转移，治疗上基本上是姑息性治疗，治疗效果差。随着抗肿瘤新药的不断出现，晚期非小细胞肺癌的疗效取得显著进展。我科于2002年5月~2005年5月采用DP 方案和 GP方案治疗晚期非小细胞肺癌68例，取得初步结果，现报告如下。 ??? 1? 对象与方法